期刊文献+

供雾化器用液体制剂的雾化特性质量控制进展 被引量:12

Progress in Quality Control of Atomization Characteristics of Inhalation Products for Nebulisation
下载PDF
导出
摘要 供雾化器用的液体制剂因其独特的优势,广泛应用于呼吸道疾病的治疗,中国药典2015版中已收载了此类制剂的质控项目及检测方法,目前国际上对此类制剂的雾化特性已经开展了大量新型检测方法的研究,为此类制剂的质量控制提供科学数据与参考,通过模拟体内药物吸收与分布的体外测定方法研究,与药物制剂的体内行为建立相关性,可更好地为临床应用提供参考。供雾化器用液体制剂的临床使用效果由雾化器和雾化溶液决定。雾化溶液的雾化特性受雾化器影响较大,因此亟需加强对雾化器的质量控制和管理,本文对此提出意见及建议。 The inhalation products for nebulisation are used widely in treatment of respiratory disease due to their unique advantages. The quality control items and methods of atomization characteristics for nebulization have been adopted in Chinese Pharmacopoeia 2015 edition. More and more new in-vitro methods of atomiza- tion characteristics were investigated worldwide for the purpose of providing the scientific support for quality control standard. The in-vitro method was carried out by simulating the absorption and distribution of drug in- vivo to establish the in-vivo and in-vitro correlation. That would provide the references for the clinical practice. The clinical efficacy of preparations for nebulisation is decided by the nebulizer and the nebulisation liquid. The atomization characteristics of the products for nebulisation are significantly influenced by nebulizers. Therefore, the quality control and administration of the nebulizers should be strengthened. The paper puts forward some comments and recommendations.
作者 陈翠翠 魏宁漪 周颖 宁保明 CHEN Cuicui;WEI Ningyi;ZHOU Ying;NING Baoming(School of Pharmacy, Yantai University, Yantai 264005, China;National Institutes for Food and Drug Control, Beijing 102629, China)
出处 《中国药品标准》 CAS 2018年第3期171-179,共9页 Drug Standards of China
基金 国家"重大新药创制"科技重大专项--化药制剂质量评价关键技术研究 吸入制剂有效性评价方法研究(2015ZX093001002009)
关键词 供雾化器用的液体制剂 呼吸模式 空气动力学粒径分布 撞击器 preparations of nebulisation breathing pattern aerodynamics particle size distribution (APSD) impactor
  • 相关文献

参考文献1

二级参考文献10

  • 1National Institute of Health, National Heart, Lung, andBlood Institute. Morbidity and mortality: 2007 chart bookon cardiovascular, lung and blood diseases [M]. Bethesda:National Institutes of Health, 2007: 65-76.
  • 2Simpson CR, Hippisley-Cox J, Sheikh A. Trends in theepidemiology of chronic obstructive pulmonary disease inEngland: a national study of 51 804 patients [J]. Br J GenPract, 2010,60(576): 277-284.
  • 3Anderson PJ. History of aerosol therapy: liquid nebulizationto MDIs to DPIs [J]. Respir Care, 2005, 50 (9): 1139-1150.
  • 4Newman S. Respiratory drug delivery: essential theory &practice [M]. River Grove: Davis healthcare internationalpublishing, 2009: 1-356.
  • 5Mitchell J,Newman S,Chan HK. In vitro and in vivo aspectsof cascade impactor tests and inhaler performance: a review[J]. AAPSPharmSciTech, 2007,8 (4): El 10.
  • 6Zhang Y, Gilbertson K, Finlay WH. In vivo-in vitrocomparison of deposition in three mouth-throat models withQvar and Turbuhaler inhalers [J]. J Aerosol Med, 2007,20 (3):227-235.
  • 7Vecellio L, Kippax P, Rouquette S, et al. Influence of realisticairflow rate on aerosol generation by nebulizers [J]. Int JPharm, 2009, 371 (1-2): 99-105.
  • 8Smaldone G, Solomita M. Predicting in vivo deposition invitro [J]. J Aerosol Med Pulm Drug Deliv, 2009,22 (1):9-10.
  • 9Zhang Y, Finlay WH. Experimental measurements of particledeposition in three proximal lung bifurcation models withan idealized mouth-throat [J]. J Aerosol Med, 2005, 18(4):460-473.
  • 10王伟,王健,王浩.噻托溴铵雾化吸入溶液的制备及体外评价[J].中国医药工业杂志,2012,43(4):268-272. 被引量:5

同被引文献129

引证文献12

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部